APA

Menke-van der Houven van Oordt C. W., Gomez-Roca C., van Herpen C., Coveler A. L., Mahalingam D., Verheul H. M. W., van der Graaf W. T. A., Christen R., Rüttinger D., Weigand S., Cannarile M. A., Heil F., Brewster M., Walz A., Nayak T. K., Guarin E., Meresse V. & Le Tourneau C. (20180215). First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. : Oncotarget.

Chicago

Menke-van der Houven van Oordt C Willemien, Gomez-Roca Carlos, van Herpen Carla, Coveler Andrew L, Mahalingam Devalingam, Verheul Henk M W, van der Graaf Winette T A, Christen Randolph, Rüttinger Dominik, Weigand Stefan, Cannarile Michael A, Heil Florian, Brewster Michael, Walz Antje-Christine, Nayak Tapan K, Guarin Ernesto, Meresse Valerie and Le Tourneau Christophe. 20180215. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. : Oncotarget.

Harvard

Menke-van der Houven van Oordt C. W., Gomez-Roca C., van Herpen C., Coveler A. L., Mahalingam D., Verheul H. M. W., van der Graaf W. T. A., Christen R., Rüttinger D., Weigand S., Cannarile M. A., Heil F., Brewster M., Walz A., Nayak T. K., Guarin E., Meresse V. and Le Tourneau C. (20180215). First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. : Oncotarget.

MLA

Menke-van der Houven van Oordt C Willemien, Gomez-Roca Carlos, van Herpen Carla, Coveler Andrew L, Mahalingam Devalingam, Verheul Henk M W, van der Graaf Winette T A, Christen Randolph, Rüttinger Dominik, Weigand Stefan, Cannarile Michael A, Heil Florian, Brewster Michael, Walz Antje-Christine, Nayak Tapan K, Guarin Ernesto, Meresse Valerie and Le Tourneau Christophe. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. : Oncotarget. 20180215.